プロモーションスケジュール Eterna Therapeutics Inc.
詳細なスケジュール
簡易グラフ
会社について
Eterna Therapeutics Inc., a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.
| Выручка |
0.0198 |
| EBITDA |
0.002 |
| Число акций ао |
0.00531 млрд |
| P/S |
0.3135 |
| P/BV |
1.22 |
| EV/EBITDA |
4.62 |
| Цена ао |
2.26 |
| P/E |
3.31 |
| ISIN |
US1140821000 |
| Сайт |
https://eternatx.com
|
| Валюта |
usd |
| IPO date |
1992-10-19 |
| Sector |
Health Care |
| Industry |
Biotechnology |
| Валюта отчета |
usd |
| 1日あたりの価格変動: |
+3.64% (0.95) |
| 週ごとの価格変動: |
-14.38% (1.15) |
| 月ごとの料金変更: |
-41.39% (1.68) |
| 3ヶ月間の価格変動: |
-45.6% (1.81) |
| 半年間の価格変動: |
-54.83% (2.18) |
| 年間の価格変動: |
-55.85% (2.23) |
| 3年間の価格推移: |
-89.61% (9.48) |
| 5年間の価格推移: |
-59.48% (2.43) |
| 年初からの価格変動: |
-25.97% (1.33) |
|
|
過小評価
| 名前 |
意味 |
学年 |
| P/S |
146.14 |
1 |
| P/BV |
4.45 |
4 |
| P/E |
0 |
0 |
| EV/EBITDA |
-2.26 |
0 |
| 合計: |
|
3.25 |
|
効率
| 名前 |
意味 |
学年 |
| ROA, % |
-44.1 |
0 |
| ROE, % |
-970.35 |
0 |
| 合計: |
|
0 |
|
|
|
配当金
| 名前 |
意味 |
学年 |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| 合計: |
|
0.0029 |
|
義務
| 名前 |
意味 |
学年 |
| Debt/EBITDA |
-0.4598 |
10 |
| 合計: |
|
10 |
|
成長の衝動
| 名前 |
意味 |
学年 |
| 収益性 Revenue, % |
-99.68 |
0 |
| 収益性 Ebitda, % |
-475.98 |
0 |
| 収益性 EPS, % |
472.69 |
10 |
| 合計: |
|
4 |
|
| スーパーバイザー |
役職 |
支払い |
生年 |
| Ms. Sandra M. Gurrola |
Principal Financial & Accounting Officer and Senior VP of Finance |
305.88k |
1967 (57 年) |
| Mr. Sanjeev Luther |
CEO, President & Director |
N/A |
1962 (62 年) |
| Ms. Dorothy J. Clarke |
General Counsel & Director |
N/A |
1966 (58 年) |
| Dr. Robert Hamilton Pierce M.D. |
Chief Scientific Officer |
|
1964 (60 年) |
